Conference Coverage

ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/25/2025
Nestoras Mathioudakis, MD, MHS
Nestoras Mathioudakis, MD, MHS, shares findings from a randomized controlled trial comparing a fully automated, app-based diabetes prevention program with a standard CDC-recognized intervention,...
06/25/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/25/2025
Nestoras Mathioudakis, MD, MHS
Nestoras Mathioudakis, MD, MHS, shares findings from a randomized controlled trial comparing a fully automated, app-based diabetes prevention program with a standard CDC-recognized intervention,...
06/25/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/25/2025
Nestoras Mathioudakis, MD, MHS
Nestoras Mathioudakis, MD, MHS, shares findings from a randomized controlled trial comparing a fully automated, app-based diabetes prevention program with a standard CDC-recognized intervention,...
06/25/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025
ADA's Scientific Sessions Coverage
ADA's Scientific Sessions Coverage
06/24/2025
Tugce Akcan, MD
In this expert interview, Tugce Akcan, MD, discusses a novel approach to type 1 diabetes care using OpenAPS and GLP-1 receptor agonists to eliminate the need for prandial insulin boluses and improve patient...
06/24/2025